Since March 2014 the REQUITE study has been registered with ISRCTN:

ISRCTN supports transparency in clinical research, helps reduce selective reporting of results and ensures an unbiased and complete evidence base.

The ISRCTN number for requite can be quoted on all REQUITE publications: ISRCTN98496463 – Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality-of-life in cancer survivors. When quoting the ISRCTN, please make sure that no space is inserted between the ISRCTN and the actual number.   For further guidance notes about how to use the ISRCTN see